Article Figures & Data
Figures
- Fig 1
Impact of NAI regimens, starting at 24 h (A) or 48 h (B) after viral challenge, on body weight loss in mice infected with 6.9 × 103 PFU (A) or 8 × 103 PFU (B) of the recombinant A/WSN/33 (H1N1) WT virus. Regimens consisted of a single dose (90 mg/kg) or multiple doses (5 × 45 mg/kg, once daily [q.d.]) of IM peramivir (Per) and low-dose (1 mg/kg, q.d.) or high-dose (10 mg/kg, q.d.) oral oseltamivir (Osel). Each symbol represents the mean weight gain or loss of 12 mice ± standard deviation (SD).
- Fig 2
Impact of NAI regimens starting at 24 h (A) or 48 h (B) after viral challenge on body weight loss in mice infected with 5.7 × 103 PFU of the recombinant A/WSN/33 (H1N1) H275Y NA mutant. Regimens consisted of a single dose (90 mg/kg) or multiple doses (5 × 45 mg/kg, q.d.) of IM peramivir and low-dose (1 mg/kg, q.d.) or high-dose (10 mg/kg, q.d.) oral oseltamivir. Each symbol represents the mean weight gain or loss of 12 mice ± SD.
Tables
- Table 1
Impact of NAI therapy starting at 24 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) WT virusa
Regimen % mortality on day 12 p.i. (n = 8) Mean % wt loss ± SD on day 5 p.i. (n = 11–12) Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4) Uninfected/untreated 0*** −3.5 ± 0.7*** Nd Untreated-infected 75 15.6 ± 1.5 2.85 × 105 ± 0.1 × 105 Oseltamivir 5 × 1 mg/kg 0*** 7.2 ± 1.2** 1.3 × 102 ± 0.65 × 102*** Peramivir 1 × 90 mg/kg 0*** −2.5 ± 0.9*** 4 × 101 ± 1 × 101*** Peramivir 5 × 45 mg/kg 0*** −2.6 ± 1.1*** 0.66 × 101 ± 0.11 × 101*** ↵a **, P < 0.01; ***, P < 0.001 (versus the untreated group). Statistical significance was determined by using Kaplan-Meier analysis for mortality and a one-way ANOVA test for weight loss and lung viral titers. Nd, not determined. The viral inoculum was 6.9 × 103 PFU.
- Table 2
Impact of NAI therapy starting at 48 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) WT virusa
Regimen % mortality on day 12 p.i. (n = 8) Mean % wt loss ± SD on day 5 p.i. (n = 11–12) Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4) Uninfected/untreated 0*** −2.8 ± 0.7*** Nd Untreated-infected 100 20.4 ± 1.1 1.6 × 106 ± 0.6 × 106 Oseltamivir 5 × 1 mg/kg 0*** 5.3 ± 0.8*** 6.6 × 101 ± 6.4 × 101*** Oseltamivir 5 × 10 mg/kg 0*** 4.4 ± 1*** 8.6 × 101 ± 4.6 × 101*** Peramivir 1 × 90 mg/kg 0*** 1.5 ± 0.7*** 2 × 101 ± 0*** Peramivir 5 × 45 mg/kg 0*** 2 ± 0.8*** 2 × 101 ± 0*** ↵a ***, P < 0.001 versus the untreated group. Statistical significance was determined by using Kaplan Meier analysis for mortality and the one-way ANOVA test for weight loss and lung viral titers. Nd, not determined. The viral inoculum was 8 × 103 PFU.
- Table 3
Impact of NAI therapy starting at 24 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) H275Y virusa
Regimen % mortality on day 12 p.i. (n = 8) Mean % wt loss ± SD on day 5 p.i. (n = 11–12) Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4) Uninfected/untreated 0*** −1.2 ± 1.1*** Nd Untreated-infected 75 16.9 ± 1.5 3.66 × 106 ± 0.11 × 106 Oselamivir 5 × 1 mg/kg 75 14 ± 1.4 3.0 × 106 ± 0.09 × 106 Oseltamivir 5 × 10 mg/kg 0*** 11.9 ± 1* 2.0 × 105 ± 0.44 × 105*** Peramivir 1 × 90 mg/kg 0*** −0.6 ± 0.9*** 8.0 × 102 ± 5.29 × 102*** Peramivir 5 × 45 mg/kg 0*** −1.3 ± 1.1*** 2.2 × 103 ± 0.6 × 103*** ↵a *, P < 0.05; ***, P < 0.001 (versus the untreated group). Statistical significance was determined by using Kaplan-Meier analysis for mortality and the one-way ANOVA test for weight loss and lung viral titers. Nd, not determined. The viral inoculum was 5.7 × 103 PFU.
- Table 4
Impact of NAI therapy starting at 48 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) H275Y virusa
Regimen % mortality on day 12 p.i. (n = 8) % wt loss ± SD on day 5 p.i. (n = 11–12) Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4) Uninfected/untreated 0*** −1.2 ± 1.1*** Nd Untreated/infected 75 16.9 ± 1.5 3.66 × 106 ± 0.11 × 106 Oseltamivir 5 × 1 mg/kg 100 18.3 ± 0.7 2.2 × 106 ± 0.52 × 106 Oseltamivir 5 × 10 mg/kg 62.5 16.5 ± 1.5 1.46 × 106 ± 0.41 × 106 Peramivir 1 × 90 mg/kg 0*** 7.9 ± 0.9*** 2.8 × 104 ± 0.7 × 104* Peramivir 5 × 45 mg/kg 0*** 9.4 ± 1.4** 3 × 103 ± 1.8 × 103*** ↵a *, P < 0.05; **, P < 0.01; ***, P < 0.001 (versus the untreated group). Statistical significance was determined by using Kaplan-Meier analysis for mortality and the one-way ANOVA test for weight loss and viral lung titers. Nd, not determined. The viral inoculum was 5.7 × 103 PFU.
